This content is only available within our institutional offering.
24 Oct 2023
Strong Q3 but new targets weigh on estimates
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Strong Q3 but new targets weigh on estimates
Probiodrug (PBD:AMS), 0 | Probiotec Limited (PBP:ASX), 0 | Probility Media Corp (PBYA:NYSE), 0 | Probiotix Health Plc (PBX:PLU), 0 | Probi AB (PROB:OME), 0 | Probi (PROB:STO), 0 | ProBility Media Corporation (PBYA:OTC), 0
- Published:
24 Oct 2023 -
Author:
ABGSC Food & Beverage Research | Sten Gustafsson -
Pages:
11
51% beat on EBITDA in Q3. New strategy and mid-term financial targets. Earnings revised up for '23e, but down for '24e-'25e.